

### UNIVERSITIES (ACADEMIC & CLINICAL RESEARCH)



### COMPANIES DEVELOPING CELL THERAPY PRODUCTS



### COMPANIES OFFERING SUPPORT SERVICES



(Disclaimer) Not restrictive\*



 **Wallonia**, a powerful ecosystem  
to boost **cell therapy products**  
**development and manufacturing**

  
**BioWin**  
THE HEALTH CLUSTER OF WALLONIA

Responsible editor: Frédéric DRUCK - BioWin asbl - Point Centre, Avenue G. Lemaître 19 - 6041 Gosselies - BELGIUM - January 2016



**BIOWIN ASBL**  
Point Centre - Avenue Georges Lemaître 19 • B-6041 Gosselies (Belgium)  
Tel.: +32 (0)71 376 386 • e-mail: [contact@biowin.org](mailto:contact@biowin.org) • blog: [www.win-health.org](http://www.win-health.org)  
\*See our website [www.biowin.org](http://www.biowin.org) to access the list of all our members  
Follow us on twitter: @BioWin\_asbl & LinkedIn: BioWin



[WWW.BIOWIN.ORG](http://WWW.BIOWIN.ORG)

# CELL THERAPY IN WALLONIA

## From Academic Excellence to Industrial Expertise

### INDUSTRIAL LEADERSHIP WITH COMPANIES DEVELOPING PRODUCTS FROM PRE-CLINICAL TO MARKET:

- **5 companies** (Bone Therapeutics, Celyad, Promethera Biosciences, Novadip Biosciences, Orgenesis)
- **With major investments:**
  - ◊ **> 329M€** private fund-raising (including 3 IPOs)
  - ◊ **> 78M€** public investments from the Walloon region

### EXCELLENCE IN ACADEMIC AND CLINICAL RESEARCH:

- **5 universities** (UCL, ULB, ULg, UMONS and UNAMUR) with more than **30 laboratories** active in cell therapy and related domains
- **> 20 000 hospital beds** available for clinical trials
- **Fastest approval process in Europe** (2 weeks) for Phase I Clinical Trials

### SERVICES FOR MANUFACTURING CELL THERAPY PRODUCTS:

- **ATMP-dedicated CDMO MaSTherCell** (600m<sup>2</sup> GMP facility)
- **Cell & Gene Therapy Lab** (LTCG) from ULg (400 m<sup>2</sup> facility)
- **Companies' cell therapy manufacturing platform** (see table)

### SUCCESS STORIES IN TECHNOLOGY-TRANSFER FROM UNIVERSITIES TO COMPANIES:

**3 spin off companies** from Belgian French speaking universities  
 Promethera Biosciences & Novadip Biosciences from **UCL**, Bone Therapeutics from **ULB**

## WALLONIA, AT THE FOREFRONT OF INNOVATION

The density and quality of health science actors in **Wallonia** have developed a **suitable ecosystem** that stimulates innovation and excellence, and allows the region to develop unique and highly specialized capacities in **health biotechnology** and **medical technologies**.

Among those actors, **5 large companies** in Biopharma (GSK, UCB, Baxter, Eurogentec and Zoetis), **5 universities** and a **hundred highly specialized and innovative SMEs**.

The companies specialized in cell therapy use the synergies created with neighboring **academic**

and **research centers** as well as with support services (including expertise in biomanufacturing of cell therapy products) in the BioWin area. This environment places **Wallonia** at the **forefront of clinical research and development in cell therapy** with five companies developing their own products.

On top of this, **Wallonia** is the region located at the very **heart of Europe**. We are also neighbor to France, Germany, Luxembourg and the Netherlands. The two airports put the region less than two hours from most European destinations.



KEY FIGURES ABOUT CELL THERAPY COMPANIES AND THEIR MANUFACTURING FACILITIES

Company name	Creation year	Total amount (M EUR) raised since their creation	Clinical Development	First product commercialization	Manufacturing facilities	M <sup>2</sup> Clean rooms	Jobs in Full time equivalent
Bone Therapeutics	2006	85	Phase III	2020	YES	250 (+600 to come mid-2016)	110
Celyad	2007	213	Phase III	2017	YES	200	95
Promethera Biosciences	2009	66.9	Phase I/II	2020	YES	400	29
Novadip Biosciences	2013	35.15	Phase I/II	>2020	YES	500	13
Orgenesis/ MaSTherCell	2011	7.5	Pre-clinical / NA	>2020 / NA	YES	600 (+600 end of 2016)	5 / 95
<b>TOTAL</b>		<b>407.5 5</b>				<b>1950 m<sup>2</sup></b>	<b>347</b>

## A UNIQUE ENVIRONMENT TO DEVELOP AND MANUFACTURE YOUR CELL THERAPY PRODUCTS

- Strong **support** to innovation in health from the **Regional Government of Wallonia**
- **Favorable tax** environment and **R&D incentives**
- Many **public** and **private investment funds** (university funds, regional and sub-regional funds, venture capital, international VCs,...) to support innovation in health
- **Excellence** in academic research and clinical development
- **European leadership** in industrialization of cell therapy products
- Large **capacities** for **manufacturing** cell therapy products.
- **Complete ecosystem** with support expertise along the value chain including universities technology transfer offices, incubators, spin off/start up, support services, etc.
- Highly qualified and multicultural **professionals**
- Relevant **education** and **training programs** to answer specific cell therapy sector needs
- Connection with **national** and **international networks** dedicated to regenerative medicine